- This topic is empty.
-
AuthorPosts
-
19/11/2026 at 17:48 #86161
Why Microbial Strain Screening Defines CRDMO Success
Microbial strain screening sits at the foundation of every successful biologics program built on E. coli or yeast expression systems. Before a single gram of drug substance reaches a GMP suite, the underlying production strain must be constructed, screened, optimized, and characterized for stability — decisions made at this early stage determine whether a program later struggles with low yields, aggregation, or costly rework. For biopharmaceutical companies, biotech startups, research institutes, and universities evaluating a microbial CRDMO partner for strain screening services, understanding what differentiates a capable provider from a generic one is essential.
Yaohai Bio-Pharma (also known as Yaohai Bio-Pharmaceutical) is a Microbial CRDMO — a Contract Research, Development, and Manufacturing Organization — founded in 2010 and specializing exclusively in microbial expression systems. Rather than treating microbial platforms as a secondary offering alongside mammalian expression, Yaohai Bio-Pharma has concentrated its technical and operational resources on E. coli and yeast systems, positioning strain screening as a core competency rather than an ancillary service.
Understanding the Industry Pain Points Behind Strain Screening
Many biologic development programs originate in mammalian expression systems, which commonly face low yields and stability issues. These limitations become especially pronounced when producing scFv/Fab fragments, which are prone to severe aggregation — a challenge that directly traces back to how strains and expression constructs are screened and optimized upstream. Compounding these technical issues, biopharmaceutical manufacturing carries high costs, and companies pursuing simultaneous entry into the US, China, and EU markets must navigate complex regulatory hurdles that make early-stage process decisions even more consequential.

Strain screening services that fail to account for these downstream realities can leave sponsors with unstable cell banks, inconsistent expression levels, or proteins that aggregate during purification — problems that are far more expensive to fix in later development phases than at strain selection.
Yaohai Bio-Pharma’s Approach to Microbial Strain Engineering
Yaohai Bio-Pharma’s microbial expression and strain engineering capabilities cover the full early-development lifecycle:
- Strain construction, screening, and optimization across both E. coli and yeast expression systems
- Cell bank establishment, ensuring reproducibility from research-grade material through to GMP manufacturing
- Strain characterization and stability studies, which validate that a selected strain will perform consistently at scale
- Expression platform development tailored to recombinant proteins, nanobodies (VHHs), and plasmid DNA
This work is supported by a dedicated E. coli expression platform and yeast expression platform, both engineered for high-yield microbial production as an alternative to mammalian systems. A notable technical differentiator is Yaohai Bio-Pharma’s proprietary refolding technology, which specifically addresses the aggregation challenges found in scFv/Fab fragments — a problem that originates partly in strain and construct design and partly in downstream processing. Project execution for this work is led by Ph.D.-level experts, reflecting the technical depth required to troubleshoot strain performance issues before they propagate into later development stages.
From Strain Screening to Scalable Manufacturing
Strain screening is only valuable if it connects seamlessly to what comes next. Yaohai Bio-Pharma operates as a one-stop CRDMO, meaning strain development work flows directly into upstream fermentation and downstream purification — including fermentation process development, process scale-up and technology transfer, protein separation and purification (chromatography and ultrafiltration), and QbD- and DoE-based process optimization. Fermentation scale-up capabilities extend up to 2,000L, and the company’s total drug substance capacity across 5 production lines reaches 7,500L, supported by 2 drug product fill-finish lines.
This continuity matters: a strain selected without visibility into fermentation and purification requirements can perform well in small-scale screening yet underdeliver at production scale. By keeping strain screening, fermentation, purification, and GMP manufacturing within a single organizational and technical framework, Yaohai Bio-Pharma reduces the handoff risk that often accompanies fragmented development pathways.
Quality and Regulatory Foundations Supporting Strain-Level Decisions
Strain screening outcomes must ultimately satisfy analytical and regulatory scrutiny. Yaohai Bio-Pharma supports this with 50+ analytical methods covering protein identity, purity, concentration, potency, and impurity analysis, along with physicochemical and microbiological testing, stability studies, specification development, and batch release testing. These capabilities are delivered within Triple ISO-certified and EU QP-audited facilities, providing a quality infrastructure that extends from early strain characterization through commercial-scale release testing.
For companies pursuing multi-region approval, this matters significantly. Yaohai Bio-Pharma has a demonstrated track record in US-China dual submissions and Australian filings, along with successful European and Australian regulatory registrations for clinical trials — directly addressing the complex regulatory hurdles that global biopharma programs face when entering the US, China, and EU markets simultaneously.

Measurable Outcomes Across the Client Base
Rather than relying on general claims, Yaohai Bio-Pharma’s track record is anchored in specific, quantified metrics: a 95% client retention rate, a 98% technology transfer success rate, and a 98% successful project delivery rate. The company reports that, compared to other CDMO companies, clients realize an average of 20% cost savings and 30% time savings. Since its founding in 2010, Yaohai Bio-Pharma has completed 200+ successful projects, including 9 Phase III clinical projects, 15 Phase II clinical projects, and over 100 IND/Phase I projects. Since 2022, the company has also supported over 800 RNA projects for universities and biotechs, demonstrating breadth beyond traditional protein and plasmid DNA work into mRNA and LNP-related development through its RNASUP mRNA platform and SORT LNP/AbLNP encapsulation technologies.
Who Benefits from Microbial Strain Screening Services
Yaohai Bio-Pharma’s strain screening and related microbial expression services are structured for a wide range of customers, including global biopharmaceutical companies, biotech startups, research institutes, and universities. Industry applications span biopharmaceutical and biologic drug development, vaccine development, oncology therapeutics, cell and gene therapy, viral vector production, medical research, and mRNA-encoded immunogen production.
Conclusion
Microbial strain screening is not an isolated technical step — it is the point at which yield, stability, manufacturability, and regulatory readiness are first determined. Organizations evaluating a microbial CRDMO for strain screening services should weigh how well a provider connects early strain work to scalable fermentation, purification, analytical testing, and global regulatory support. With over 16 years of specialization in microbial expression systems, proprietary refolding technology, quantified delivery metrics, and a one-stop CRDMO structure from R&D through GMP manufacturing, Yaohai Bio-Pharma (Yaohai Bio-Pharmaceutical) represents a microbial-focused alternative for sponsors seeking to resolve the low-yield and stability challenges commonly associated with mammalian expression systems.
http://www.yaohaibio-pharma.com
Yaohai Bio-Pharma -
AuthorPosts
- You must be logged in to reply to this topic.